Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

Trader Joe's Recalls Garlic Cheese Curds Due to Listeria Risk

MONDAY, June 23, 2025 A cheese sold at Trader Joe s has been recalled due to possible listeria contamination. The product is Face Rock Creamery s Vampire Slayer

100,000 Amazon Mattresses Recalled Over Fire Hazard

MONDAY, June 23, 2025 If you bought a Crayan mattress on Amazon in the last two years, you may need to stop using it right away. About 100,000 mattresses are be

FDA Recalls Chocolate Candies Over Milk Allergy Risk

MONDAY, June 23, 2025 Chocolate candy sold across the U.S. is being recalled because it may contain milk that isn t listed on the label, the U.S. Food and Drug

Minor Complications Up for Black Patients After Weight-Loss Surgery

Black patients have a higher incidence of minor complications after metabolic and bariatric surgery, according to a study presented at the annual meeting of the

Deep Sleep, Daytime Control Key to Nocturnal Enuresis Management

Specific factors, including deep sleep and daytime urinary control, are associated with treatment-responsive nocturnal enuresis among children, according to a s

Gluten-Stimulated Interleukin-2 Secretion Useful for Diagnosing Celiac Disease

Gluten-stimulated interleukin-2 (IL-2) secretion is useful for diagnosis of celiac disease (CeD), according to a study published online June 9 in Gastroenterolo

Hydrops MRI Accurately Differentiates Meniere Disease, Vestibular Migraine

The combination of cochlear endolymphatic hydrops (CEH) and vestibular endolymphatic hydrops (VEH) on magnetic resonance imaging (MRI) accurately diagnoses Meni

FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphom

Lilly's Oral GLP-1, Orforglipron, Showed Compelling Efficacy and a Safety Profile Consistent with Injectable GLP-1 Medicines, in Complete Phase 3 Results

Eli Lilly and Company (NYSE LLY) today announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron compared to

Lilly's Once-Weekly Insulin Efsitora Alfa Demonstrated A1C Reduction and a Safety Profile Consistent with Daily Insulin in Multiple Phase 3 Trials

Eli Lilly and Company (NYSE LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy

Popular Keywords